Veradermics Incorporated (MANE) exhibits 41.0% gross margins and -11.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 7.1% implied options volatility.
Sustained 41.0% gross profitability converts into -4.3% operating margin and -11.9% ROIC, outpacing sector cost of capital.
ROIC: -11.9% // GM: 41.0%YoY revenue trajectory of +4.4% paired with -1.19% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +4.4% // FCF YLD: -1.19%Altman Z-Score of 26.00 and Piotroski F-Score of 4/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 4/9Trading at 24.0x trailing P/E (24.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.1% implied move with a 0.72 put/call ratio around $141.00 max pain.
IMPL MOVE: ±7.1% // P/C: 0.72Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -4.2% net margins.
NET MARGIN: -4.2% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MANE & activate live FRED threshold breach alerts.